Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.

Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova   
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. The Company’s fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps their customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

Investor Contact
Matt Lowell 
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100 

Media Contact
Jennifer Henry
Senior Vice President, Marketing 
jenn.henry@teknova.com
+1 831-313-1259

This press release was published by a CLEAR® Verified individual.

Staff

Recent Posts

Netsmart Showcases Meaningful AI and New Innovations of the CareFabric® Platform to Optimize Community-Based Care at NatCon25

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#Acquisition--Netsmart, an industry-leading provider of healthcare IT for human services and post-acute…

29 minutes ago

AV Laboratories Appoints Roula Youssef Halabi to Business Advisory Board to Expand Presence in UAE and Middle East

NEW YORK--(BUSINESS WIRE)--AV Laboratories, a leader in science-backed skincare and luxury skin longevity, proudly announces…

30 minutes ago

Eight Student Teams Named National Winners of 33rd Annual ExploraVision Competition

Toshiba and the National Science Teaching Association (NSTA) honor student innovation with prizes and award…

34 minutes ago

Psomagen Selected as Key Service Provider, Will Utilize Ultima Genomics’ UG 100™ Sequencer to Accelerate Chan Zuckerberg Initiative’s Billion Cells Project

ROCKVILLE, Md., May 5, 2025 /PRNewswire/ -- Psomagen Inc., a multiomics service laboratory serving academic,…

39 minutes ago

Arctic Quest: 8,000-Mile Motorcycle Ride Honors Indigenous Women and Girls

Our Rescue, Mental Health Tech Company and First Nations Advocate Unite to Raise Awareness and…

39 minutes ago

Digital Twins in Healthcare Market worth US$59.94 billion by 2030 with 68.0% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., May 5, 2025 /PRNewswire/ -- The global Digital Twins in Healthcare Market,…

39 minutes ago